(Reuters) – AstraZeneca of Britain (AZN.L) Said on Thursday that there was good data coming in the vaccine for COVID-19 so far, already as front-runner in large-scale human trials and in the race for a shot against the widely novel coronavirus. Was seen in
An employee is seen at the Special Center for Immunology (CRIE) of the Federal University of São Paulo (Unifesp) at the Oxford / AstraZeneca coronavirus vaccine on June 24, 2020 in Sao Paulo, Brazil. REUTERS / Amanda Perobelli
The drugmaker, Britain’s most valuable listed company, also announced second-quarter results, beating its sales and profit projections to a strong demand from a diverse product line-up.
“Vaccine development is progressing well. We had good data so far. We need to show efficacy in the clinical program, but so far, so good, ”Chief Executive Pascal Soriot said on a media call.
AstraZeneca has already signed a deal with countries to make more than 2 billion doses of its COVID-19 vaccine, developed in partnership with the University of Oxford, and says it could be approved by the end of this year is.
The company was busy for a few months: it took on the development of COVID-19 Shot, received billions in government money, signed several supply deals, and was even the subject of a mega-merger speculation – all Business while marching with its origin.
It stuck to its 2020 outlook on Thursday, and after three months of product sales of $ 6.05 billion, its shares were up nearly 3% at 88.6 pounds to overtake the $ 6.01 billion consensus. The figure excludes payments from tie-ups.
New drugs for diabetes, heart conditions and cancer, including the top-selling lung cancer drug Tagrisso, performed well in the quarter and AstraZeneca is on track to grow for the third consecutive year.
Among medicines with better-than-expected revenue, sales of the respiratory drug Symbicort rose 12% to $ 653 million, nearly $ 90 million more than consensus, while cancer drug Lingarza’s revenue jumped 62% to $ 554 million. Gone.
There are no approved vaccines for the disease caused by the new virus, but AstraZeneca’s shot is widely considered to be the leading candidate after the results of early-stage human trials showed it was safe and produced an immune response. used to do.
Key earnings of 96 cents per share beat analysts’ expectations of 93 cents. Total revenue grew by 11%.
Reporting by Pushkala Aripaka in Bengaluru and Ludwig Berger in Frankfurt; Additional reporting by Ankur Banerjee; Editing by Saumyadev Chakraborty